DRIO Quote, Financials, Valuation and Earnings

GoodRx Holdings, Inc. has a net margin of -41.48% compared to DarioHealth Corp.'s net margin of 0.57%. DarioHealth Corp.'s return on equity of -41.55% beat GoodRx Holdings, Inc.'s return on equity of 4.78%.

DarioHealth Corp. has a consensus price target of $18.25, signalling upside risk potential of 54.01%. On the other hand GoodRx Holdings, Inc. has an analysts' consensus of $5.09 which suggests that it could grow by 85.74%. Given that GoodRx Holdings, Inc. has higher upside potential than DarioHealth Corp., analysts believe GoodRx Holdings, Inc. is more attractive than DarioHealth Corp..

DarioHealth Corp. has a beta of 1.077, which suggesting that the stock is 7.716% more volatile than S&P 500. In comparison GoodRx Holdings, Inc. has a beta of 1.470, suggesting its more volatile than the S&P 500 by 47.004%.

DarioHealth Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GoodRx Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DarioHealth Corp. pays -- of its earnings as a dividend. GoodRx Holdings, Inc. pays out -- of its earnings as a dividend.

DarioHealth Corp. quarterly revenues are $5M, which are smaller than GoodRx Holdings, Inc. quarterly revenues of $196M. DarioHealth Corp.'s net income of -$2.1M is lower than GoodRx Holdings, Inc.'s net income of $1.1M. Notably, DarioHealth Corp.'s price-to-earnings ratio is -- while GoodRx Holdings, Inc.'s PE ratio is 31.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DarioHealth Corp. is 6.58x versus 1.26x for GoodRx Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

National Research Corp. has a net margin of -41.48% compared to DarioHealth Corp.'s net margin of 11.54%. DarioHealth Corp.'s return on equity of -41.55% beat National Research Corp.'s return on equity of 61.55%.

DarioHealth Corp. has a consensus price target of $18.25, signalling upside risk potential of 54.01%. On the other hand National Research Corp. has an analysts' consensus of -- which suggests that it could fall by --. Given that DarioHealth Corp. has higher upside potential than National Research Corp., analysts believe DarioHealth Corp. is more attractive than National Research Corp..

DarioHealth Corp. has a beta of 1.077, which suggesting that the stock is 7.716% more volatile than S&P 500. In comparison National Research Corp. has a beta of 0.447, suggesting its less volatile than the S&P 500 by 55.256%.

DarioHealth Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. National Research Corp. offers a yield of 2.97% to investors and pays a quarterly dividend of $0.12 per share. DarioHealth Corp. pays -- of its earnings as a dividend. National Research Corp. pays out 45.99% of its earnings as a dividend. National Research Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

DarioHealth Corp. quarterly revenues are $5M, which are smaller than National Research Corp. quarterly revenues of $34.6M. DarioHealth Corp.'s net income of -$2.1M is lower than National Research Corp.'s net income of $4M. Notably, DarioHealth Corp.'s price-to-earnings ratio is -- while National Research Corp.'s PE ratio is 22.94x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DarioHealth Corp. is 6.58x versus 2.65x for National Research Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Predictive Oncology, Inc. has a net margin of -41.48% compared to DarioHealth Corp.'s net margin of -2156852.78%. DarioHealth Corp.'s return on equity of -41.55% beat Predictive Oncology, Inc.'s return on equity of -1065.31%.

DarioHealth Corp. has a consensus price target of $18.25, signalling upside risk potential of 54.01%. On the other hand Predictive Oncology, Inc. has an analysts' consensus of -- which suggests that it could grow by 716.7%. Given that Predictive Oncology, Inc. has higher upside potential than DarioHealth Corp., analysts believe Predictive Oncology, Inc. is more attractive than DarioHealth Corp..

DarioHealth Corp. has a beta of 1.077, which suggesting that the stock is 7.716% more volatile than S&P 500. In comparison Predictive Oncology, Inc. has a beta of 1.354, suggesting its more volatile than the S&P 500 by 35.357%.

DarioHealth Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Predictive Oncology, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DarioHealth Corp. pays -- of its earnings as a dividend. Predictive Oncology, Inc. pays out -- of its earnings as a dividend.

DarioHealth Corp. quarterly revenues are $5M, which are larger than Predictive Oncology, Inc. quarterly revenues of $3.6K. DarioHealth Corp.'s net income of -$2.1M is higher than Predictive Oncology, Inc.'s net income of -$77.6M. Notably, DarioHealth Corp.'s price-to-earnings ratio is -- while Predictive Oncology, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DarioHealth Corp. is 6.58x versus 16.89x for Predictive Oncology, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Spok Holdings, Inc. has a net margin of -41.48% compared to DarioHealth Corp.'s net margin of 9.46%. DarioHealth Corp.'s return on equity of -41.55% beat Spok Holdings, Inc.'s return on equity of 10.88%.

DarioHealth Corp. has a consensus price target of $18.25, signalling upside risk potential of 54.01%. On the other hand Spok Holdings, Inc. has an analysts' consensus of $20.00 which suggests that it could grow by 60.06%. Given that Spok Holdings, Inc. has higher upside potential than DarioHealth Corp., analysts believe Spok Holdings, Inc. is more attractive than DarioHealth Corp..

DarioHealth Corp. has a beta of 1.077, which suggesting that the stock is 7.716% more volatile than S&P 500. In comparison Spok Holdings, Inc. has a beta of 0.438, suggesting its less volatile than the S&P 500 by 56.19%.

DarioHealth Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Spok Holdings, Inc. offers a yield of 9.53% to investors and pays a quarterly dividend of $0.31 per share. DarioHealth Corp. pays -- of its earnings as a dividend. Spok Holdings, Inc. pays out 171.77% of its earnings as a dividend.

DarioHealth Corp. quarterly revenues are $5M, which are smaller than Spok Holdings, Inc. quarterly revenues of $33.9M. DarioHealth Corp.'s net income of -$2.1M is lower than Spok Holdings, Inc.'s net income of $3.2M. Notably, DarioHealth Corp.'s price-to-earnings ratio is -- while Spok Holdings, Inc.'s PE ratio is 16.39x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DarioHealth Corp. is 6.58x versus 1.95x for Spok Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.